Related references
Note: Only part of the references are listed.Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
Emanuela Sant'Antonio et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK
Natalia Curto-Garcia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Anticoagulant therapy for splanchnic vein thrombosis ISTH SSC Subcommittee Control of Anticoagulation
Marcello Di Nisio et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation
Kai Wille et al.
ANNALS OF HEMATOLOGY (2019)
From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms
Brady L. Stein et al.
BLOOD (2019)
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)
Annie M. Young et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms
Valerio De Stefano et al.
BLOOD CANCER JOURNAL (2018)
Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study
Kirstine Kobberoe Sogaard et al.
LANCET HAEMATOLOGY (2018)
Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms - long term follow-up of a regional case series
Graeme Greenfield et al.
THROMBOSIS JOURNAL (2018)
Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms
Jean-Christophe Ianotto et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia A Systematic Review
Derek K. Chu et al.
ANNALS OF INTERNAL MEDICINE (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
V. De Stefano et al.
BLOOD CANCER JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Rayyan-a web and mobile app for systematic reviews
Mourad Ouzzani et al.
SYSTEMATIC REVIEWS (2016)
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis Results of an International Registry
Walter Ageno et al.
JAMA INTERNAL MEDICINE (2015)
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study
Ida Martinelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology
Tiziano Barbui et al.
BLOOD (2014)
Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases
Francesco Dentali et al.
THROMBOSIS RESEARCH (2014)
Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis
Jasper H. Smalberg et al.
BLOOD (2012)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
Alessandra Carobbio et al.
BLOOD (2011)
Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms
J. Hoekstra et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
Valerio De Stefano et al.
HAEMATOLOGICA (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis
F Passamonti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)